Long-term Outcomes of Testosterone Treatment in Men: A T4DM Postrandomization Observational Follow-up Study
Authors' conclusion
We conclude that randomized T treatment for 24 months in men with impaired glucose tolerance or new diabetes but without pathological hypogonadism was associated with higher levels of self-reported benefits and diagnosis of sleep apnea during, but not after, the study as well as more frequent prescribed poststudy T treatment consistent with androgen dependence in some men receiving prolonged injectable TU.
Study context
- Population
- Men with impaired glucose tolerance or newly diagnosed diabetes randomized in T4DM (1007 men)59% completed surveys
- Participants
- 599 men
- Comparison
- Testosterone undecanoate vs placebo
- Testosterone undecanoate (TU)n = 316
- Pn = 283reference
Methodological detailsemail survey, Follow-up email survey after a median of 5.1 years since last injection
- Email survey
- Follow-up email survey after a median of 5.1 years since last injection
Primary result
As reported in the abstract
P < 0.001
Further findings
Belief in study benefits
P = 0.07
Resuming prescribed T treatment · poststudy
P = 0.03
Self-reported new diabetes, prostate or CVD; weight maintenance or weight loss behaviors · 5 years after cessation
- No difference in self-reported new diagnosis of diabetes, prostate or CVD, nor change in weight maintenance or weight loss behaviors
Safety
New diagnosis of sleep apnea · during the study
P = 0.03
- New diagnosis of sleep apnea — Sleep apnea at T4DM entry
- 25%
New diagnosis of sleep apnea · during the study
- Not more frequent after the study
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →